Clinical Trial

A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
Researchers are looking for new treatments for HIV-1 (human immunodeficiency virus type 1) that are safe, well-tolerated, and can be taken less often. HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. Ulonivirine (MK-8507) is a study medicine designed to treat HIV-1 The goal of this study is to learn if ulonivirine does not increase the QT interval (a measure of heart rhythm on an electrocardiogram) above a certain amount. Researchers also want to learn what happens to the amount of ulonivirine in a healthy person's body over time.
Protocol Amendment History 1 change
critical Trial completed 2026-04-22
Trial Details
NCT Number NCT07305831
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy
Enrollment 62 participants
Start Date 2026-01-22
Primary Completion 2026-04-09 (estimated)
Study Completion 2026-04-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-21